Mon–Thu 8am–4:30pm CT · Fri 8am–3pm CT
Clinical Trial · NCT04008095
Overview
A lot of studies have demonstrated the prognostic value of post therapy 18F-FDG PET/CT in the management of uterine cervical cancer. Post therapy 18F-FDG PET/CT is usually requested by a lot of clinicians. Whereas 18F-FDG PET/CT is useful for prognosis in the follow-up, data are yet insufficient to clearly establish a formal recommendation. This prospective multicenter observational study will evaluate the interest of post therapy 18F-FDG PET/CT in clinical management (within 2 months of treatment) in patients with cervical cancer at an advanced stage.
Sponsor
University Hospital, Brest
Phase
N/A
Contacts
Alexandra LE DUC-PENNEC
alexandra.leduc-pennec@chu-brest.fr
+33 2 98 22 31 19
ClinicalTrials.gov
NCT04008095Drug / Compound
Help us improve your experience